Udhayvir Grewal, Resident Physician at Ochsner LSU Health Shreveport Academy Medical Centre, shared a post on X by Erman Akkus, Medical Oncology Fellow at Ankara University, adding:

“Impressive data for PDAC outcomes by metastatic site.

Lung mets – immunogenic TIME – better biology – better outcomes.

Perfect use of metastasis-directed therapy if oligometastatic and lung only mets.

Now we have prospective data for PFS benefit in all comers population with oligometastatic PDAC-EXTEND trial.”

Quoting Erman Akkus’s post about a paper by Emily Alouani et al. published in ESMO GI Oncology:

“Metastatic site and survival in pancreatic cancer.

mOS and mPFS

lung-only > peritoneum-only >liver-only >multi-site
lung-only accounts 4.7% of syn met pancreatic cancers

More agressive local therapies in this subset?”

“Is survival influenced by metastatic site in synchronous metastatic pancreatic adenocarcinoma (PDAC)? A prospective real-world BACAP study”

Authors: Emily Alouani et al.

Udhayvir Grewal: Impressive data for PDAC outcomes by metastatic site

More posts featuring Udhayvir Grewal and Erman Akkus.